Abstract 189P
Background
NF-κB-interacting LncRNA (NKILA) plays an inhibitory role in the NF-κB pathway, which is a key regulator of inflammatory cytokines. These mediators, freely floating in ascitic fluid (AF), reflecting the molecular genetic characteristics of tumor cells in ovarian cancer (OC), and associated with epigenetic switches of key pathways of carcinogenesis remain poorly understood. The aim of the work was to study the expression of LncRNA NKILA and marker cytokines of the NF-kB pathway in ascites of patients with OC.
Methods
The study included 22 patients with ascitic OC at stage III-IV according to FIGO. Isolation of circulating nucleic acid was performed from 2 ml of the cell-free fraction of ascites before treatment using SileksMagNaDirect magnetic particles (Sileks, Russia). lncRNA NKILA expression in AF was determined by qPCR (CFX-96, BioRad). Determination of cytokines VEGFA, IL-6, MCP-1 in AF was performed by ELISA. According to the effect of platinum-containing chemotherapy (CT), the patients were divided into groups: 1 - progression against the background of CT and early relapse; 2 - nonrelapsive. Statistical data processing was carried out using Statistica 13.0.
Results
The study included 22 patients with ascitic OC at stage III-IV according to FIGO. Isolation of circulating nucleic acid was performed from 2 ml of the cell-free fraction of ascites before treatment using SileksMagNaDirect magnetic particles (Sileks, Russia). lncRNA NKILA expression in AF was determined by qPCR (CFX-96, BioRad). Determination of cytokines VEGFA, IL-6, MCP-1 in AF was performed by ELISA. According to the effect of platinum-containing chemotherapy (CT), the patients were divided into groups: 1 - progression against the background of CT and early relapse; 2 – non-relapsive. Statistical data processing was carried out using Statistica 13.0.
Conclusions
Thus, the study of the lncRNA NKILA profile in tumor ascites in relation to inflammatory cytokines of the NF-kB signaling pathway requires further study in the context of understanding the signatures in the formation of chemoresistance in advanced OC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
186P - Degradation of BRCA2 expression by hyperthermia sensitizes HRD-negative (BRCA2 wild-type) ovarian cancer cells to niraparib
Presenter: Junyang Li
Session: Poster viewing 03
187P - BUB1 (2530C>T) polymorphism and expression affects chemotherapy response and predicts poor prognosis in advanced epithelial ovarian cancer
Presenter: Sinjini Sarkar
Session: Poster viewing 03
188P - Spatial transcriptomic analysis of tumor tissue in ovarian cancer patients treated with neoadjuvant chemotherapy
Presenter: Irina Larionova
Session: Poster viewing 03
190P - Real-world applications of poly (ADP-ribose) polymerase inhibitors for ovarian cancer: A single-center study in China
Presenter: dengfeng wang
Session: Poster viewing 03
191P - Phase II study of sodium valproate in combination with oral etoposide in platinum-resistant ovarian cancer
Presenter: N Thejeswar
Session: Poster viewing 03
192P - Human epididymis protein 4 as a predictor of response to neoadjuvant chemotherapy in epithelial ovarian cancer
Presenter: Sarada Planjery
Session: Poster viewing 03
193P - Experience with olaparib in the treatment of BRCA-associated tumors in real clinical practice: Experience of re-challenge mode of olaparib usage
Presenter: Alexander Sultanbaev
Session: Poster viewing 03
194P - A study of the treatment response of concomitant external beam radiotherapy (EBRT) and intracavitary brachytherapy in the management of locally advanced carcinoma of uterine cervix
Presenter: Asish Chowdhury
Session: Poster viewing 03
195P - Awareness of human papillomavirus (HPV) infection, cervical cancer (CC), and vaccine among females in Sultanate of Oman
Presenter: Abdulrahman Al-Mirza
Session: Poster viewing 03
196P - Short course brachytherapy in locally advanced cervical cancer: Safety and response rate
Presenter: Maryam Garousi
Session: Poster viewing 03